GLP-1 & Incretin Science

Normal Human Thyroid Has No Detectable GLP-1 Receptors

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Waser and colleagues measured incretin receptors across rodent and human thyroid tissue. GLP-1 receptors are present in normal rat and mouse C-cells, and reach 100% incidence in rat C-cell hyperplasia and medullary thyroid carcinoma. No GLP-1 or GIP receptors were detected in normal human thyroid.

Key facts

Study
Waser 2011, Neuroendocrinology (PMID 21893952)
Method
In vitro receptor autoradiography
Normal rodent C-cells
GLP-1 receptors present
Rat C-cell hyperplasia and MTC
GLP-1R incidence 100%
Normal human thyroid
No GLP-1 or GIP receptors detected
Human MTC, GLP-1R
27%
Human MTC, GIP receptors
Up to 89%, high density

Why receptor expression is the decisive question

The rodent effect was characterised as on-target: it proceeds through the GLP-1 receptor. An on-target effect requires the target. If human C-cells express the receptor at much lower density than rodent C-cells, the same drug would engage far less of the same pathway, and the rodent finding would not straightforwardly predict a human one.

What the measurements showed in rodents

GLP-1 receptors are expressed in C-cells of normal rat and mouse thyroid. Their density is markedly increased in rat C-cell hyperplasia and medullary thyroid carcinoma, where incidence reaches 100%. GIP receptors are absent from normal rodent thyroid and from C-cell hyperplasia, but present in all rat medullary thyroid carcinomas.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What they showed in humans

No GLP-1 or GIP receptors were detected in normal human thyroid at all. Among human medullary thyroid carcinomas, 27% expressed GLP-1 receptors while up to 89% expressed GIP receptors at high density. TT cells, a human medullary thyroid carcinoma line, lack GLP-1 receptors and express GIP receptors.

The asymmetry that is rarely stated

The boxed warning concerns GLP-1 receptor agonists and derives from rodent data. In human medullary thyroid carcinoma, the abundantly expressed incretin receptor is GIP at up to 89%, while GLP-1 is the rarer one at 27%. That is a receptor distribution observation, not evidence of harm from anything, and it does not appear in most discussion of this warning.

What this does and does not license concluding

It provides a mechanistic reason the rodent finding might not extend to humans, a reason grounded in measurement rather than assertion. It does not demonstrate safety. Receptor autoradiography describes what is present in tissue; whether an exposure produces an outcome over years is an epidemiological question, answered separately and by different methods.

Why the label wording is careful

Regulatory labelling states that it is unknown whether these agents cause thyroid C-cell tumours in humans, and that the human relevance of the rodent findings has not been determined. That is an accurate description of the position: a serious rodent signal, a species difference with a plausible mechanistic basis, and no resolution from the toxicology itself.

Quick reference

TissueGLP-1 receptorsGIP receptors
Normal rat/mouse thyroid C-cellsPresentNot detected
Rat C-cell hyperplasia and MTC100% incidencePresent in all rat MTC
Normal human thyroidNot detectedNot detected
Human medullary thyroid carcinoma27%Up to 89%, high density

Frequently asked questions

Do human thyroids have GLP-1 receptors?

Waser 2011 detected no GLP-1 or GIP receptors in normal human thyroid, in contrast to normal rat and mouse C-cells where GLP-1 receptors are present.

Does that mean the drugs are safe for the thyroid?

No. It gives a mechanistic reason the rodent finding may not extend to humans. Whether an exposure produces an outcome is an epidemiological question answered by different methods.

Which incretin receptor is common in human MTC?

GIP, at up to 89% with high density. GLP-1 receptors appear in only 27%, the reverse of what the warning's framing suggests.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.